**Supplement 1: Papers included in analysis**

Antonic A, Sena ES, Donnan GA, Howells DW. Human in vitro models of ischaemic stroke: a test bed for translation. Translational stroke research. 2012;3(3):306-9.

Bath PM, Macleod MR, Green AR. Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. International Journal of Stroke. 2009;4(6):471-9.

Bix GJ, Fraser JF, Mack WJ, Carmichael ST, Perez-Pinzon M, Offner H, Sansing L, Bosetti F, Ayata C, Pennypacker KR. Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical. Translational stroke research. 2018;9(3):258-66.

Boltze J, Ayata C, Wagner DC, Plesnila N. Preclinical phase III trials in translational stroke research: call for collective design of framework and guidelines. Stroke. 2014:42(2):357-357.

Boltze J, Wagner DC, Barthel H, Gounis MJ. Academic-industry collaborations in translational stroke research. Translational stroke research. 2016;7(4):343-53.

Boltze J, Ayata C. Challenges and controversies in translational stroke research - an introduction. Translational Stroke Research. 2016;7: 355-357.

Bosetti F, Koenig JI, Ayata C, Back SA, Becker K, Broderick JP, Carmichael ST, Cho S, Cipolla MJ, Corbett D, Corriveau RA. Translational stroke research: vision and opportunities. Stroke. 2017;48(9):2632-7.

Budincevic H, Bielen I, Csiba L. Translational challenges of neuroprotection strategy in ischemic stroke. Translational Neuroscience. 2011;2(4):344-50.

Cheng, Y.D.; Al-Khoury, L.; Zivin, J.A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1:36–45.

Cook DJ, Tymianski M. Translating promising preclinical neuroprotective therapies to human stroke trials. Expert review of cardiovascular therapy. 2011;9(4):433-49.

Curry SH. Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. Ann N Y Acad Sci. 2003;993:69–74, discussion 79.

Davis SM, Donnan GA. Neuroprotection: establishing proof of concept in human stroke. Stroke. 2002;33(1):309-10.

deGraba TJ, Pettigrew LC. Why do neuroprotective drugs work in animals but not humans? Neurologic clinics. 2000;18(2):475-93.

del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1 Drugs promoting cerebral blood flow. Journal of internal medicine. 1995;237(1):79-88.

del Zoppo GJ. Clinical trials in acute stroke: why have they not been successful? Neurology. 1998;51(3 suppl 3):S59–S61.

Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006;26:1465–1478.

Dirnagl U, Macleod MR. Stroke research at a road block: the streets from adversity should be paved with meta‐analysis and good laboratory practice. British journal of pharmacology. 2009;157(7):1154-6.

Dirnagl U, Fisher M. International, multicenter randomized preclinical trials in translational stroke research: it’s time to act. J Cereb Blood Flow Metab. 2012;32:933–935.

Dirnagl U, Hakim A, Macleod M, Fisher M, Howells D, Alan SM, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke. 2013;44:1754–1760.

Dirnagl U. Modeling immunity and inflammation in stroke: can mice be trusted?. Stroke. 2014;45(9):e177-8.

Dirnagl U, Endres M. Found in translation: preclinical stroke research predicts human pathophysiology, clinical phenotypes, and therapeutic outcomes. Stroke. 2014;45(5):1510-8.

Dirnagl U. Thomas Willis lecture: is translational stroke research broken, and if so, how can we fix it?. Stroke. 2016;47(8):2148-53.

Donnan GA, Davis SM. Stroke drug development: usually, but not always, animal models. Stroke. 2005;36(10):2326-.

Donnan GA, Davis SM. Neuroprotection: still achievable in humans. Stroke. 2008;39(2):525.

Donnan GA. A new road map for neuroprotection. Stroke. 2008;39(1):242-8.

Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis. 2008;25:268–278.

Fisher M, Tatlisumak T. Use of animal models has not contributed to development of acute stroke therapies: con. Stroke. 2005;36(10):2324-5.

Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244-50.

Fisher M. New approaches to neuroprotective drug development. Stroke. 2011;42(1\_suppl\_1):S24-7.

Fisher M. The spectrum of translational stroke research. Neurological research. 2013;35(5):443-7

Feuerstein GZ, Chavez J. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke. 2009;40(3\_suppl\_1):S121-5.

Ginsberg MD. The validity of rodent brain-ischemia models is self-evident. Arch Neurol. 1996; 53: 1065-1067; discussion 1070.

Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke. 2009;40(3\_suppl\_1):S111-4.

Ginsberg MD. Invited editorial: current impediments to successful translational research in stroke. Translational Stroke Research. 2010;1:155-157

Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123-36.

Green AR, Odergren T, Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003; 24:402–8.

Green AR. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. British journal of pharmacology. 2008;153(S1):S325-38.

Greenberg DA. Preclinical stroke research: gains and gaps. Stroke. 2013;44(601):S114.

Grotta J. Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J Intern Med 1995; 237:89–94.

Grotta J. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside: the Feinberg lecture. Stroke. 1999;30:1722–1728.

Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 2002;33(1):306-7.

Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants, Selim M, Hanley D, Broderick J, Goldstein JN, Gregson BA, Falcione G, Gonzales NR, Gurol E, Kersten J, Lewkowicz H. Basic and Translational Research in Intracerebral Hemorrhage: Limitations, Priorities, and Recommendations. Stroke. 2018;49(5):1308-14.

Herson PS, Traystman RJ. Animal models of stroke: translational potential at present and in 2050. Future neurology. 2014;9(5):541-51.

Howells DW, Sena ES, O'collins V, Macleod MR. Improving the efficiency of the development of drugs for stroke. International Journal of Stroke. 2012;7(5):371-7.

Howells DW, Macleod MR. Evidence-based translational medicine. Stroke. 2013;44(5):1466-71.

Howells DW, Sena ES, Macleod MR. Bringing rigour to translational medicine. Nature Reviews Neurology. 2014;10(1):37.

Hoyte L, Kaur J, Buchan AM. Lost in translation: taking neuroprotection from animal models to clinical trials. Experimental neurology. 2004;188(2):200-4.

Hsu CY. Criteria for valid preclinical trials using animal stroke models. Stroke. 1993;24(5):633-6.

Hunter AJ, Green AR, Cross DT. Animal models of acute ischemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol Sci. 1995;16:123–128.

Hussain MS, Shuaib A. Research into neuroprotection must continue… But with a different approach. Stroke. 2008;39(2):521-2.

Kaste M. Use of animal models has not contributed to development of acute stroke therapies: pro. Stroke. 2005;36(10):2323-4.

Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841-3.

Lapchak PA. Translational stroke research opportunities and a strategy to develop effective cytoprotection. Translational Stroke Research. 2017;8:318–321.

Lees KR. Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke. 2002;33(1):308-9.

Lo EH. 2013 Thomas Willis Award Lecture: causation and collaboration for stroke research. Stroke. 2014;45(1):305-8.

Lyden P, Lapchak P. Sisyphus and translational stroke research. Science translational medicine. 2012;4(156):20-.

Macleod MR, Fisher M, O'collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, Van Der Worp HB, Traystman RJ, Minematsu K, Donnan GA. Reprint: Good laboratory practice: preventing introduction of bias at the bench. Journal of Cerebral Blood Flow & Metabolism. 2009;29(2):221-3.

Marbacher S. Can quality improvement tools overcome the translational roadblock—the vital influence of the researcher. Translational stroke research. 2017;8(3):203-5.

Millikan C. Animal stroke models. Stroke. 1992;23(6):795-7.

Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. International journal of molecular sciences. 2012;13(9):11753-72.

Molinari GF. Why model strokes?. Stroke. 1988;19(10):1195-7.

Moskowitz MA. Brain protection: maybe yes, maybe no. Stroke. 2010;41(10\_suppl\_1):S85-6.

Neuhaus AA, Rabie T, Sutherland BA, Papadakis M, Hadley G, Cai R, Buchan AM. Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke. JAMA neurology. 2014;71(5):634-9.

Neuhaus AA, Couch Y, Hadley G, Buchan AM. Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain. 2017;140(8):2079-92.

Offner H. Modeling immunity and inflammation in stroke: don't be afraid of mice?. Stroke. 2014;45(9):e181-2.

Perez de La Ossa N, Dávalos A. Neuroprotection in cerebral infarction: the opportunity of new studies. Cerebrovascular Diseases. 2007;24(Suppl. 1):153-6.

Röther J. Neuroprotection does not work!. Stroke. 2008;39(2):523-524.

Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol. 2007;61:396–402.

Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke?. Trends in neurosciences. 2007;30(9):433-9.

Sharp FR, Jickling GC. Modelling immunity and inflammation in stroke: Differences between rodents and humans?. Stroke; a journal of cerebral circulation. 2014;45(9):e179.

STAIR (Stroke Therapy Academic Industry Roundtable). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752.

Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. International Journal of Stroke. 2012;7(5):407-18.

Suzuki H, Nakano F. To improve translational research in subarachnoid hemorrhage. Translational Stroke Research. 2018;9:1–3.

Turner RJ, Jickling GC, Sharp FR. Are underlying assumptions of current animal models of human stroke correct: from STAIRs to high hurdles?. Translational stroke research. 2011;2(2):138-43.

Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients? Yes, but not the way we tried it before. Stroke. 2010;41(10\_suppl\_1):S87-90.

Waltz AG. Clinical relevance of models of cerebral ischemia. Stroke. 1979;10(2):211-3.

Wiebers DO, Adams Jr HP, Whisnant JP. Animal models of stroke: are they relevant to human disease?. Stroke. 1990;21(1):1-3.

Xu SY, Pan SY. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Medical science monitor basic research. 2013;19:37.

Zerna C, Hill MD, Boltze J. Towards Improved Translational Stroke Research: Progress and Perspectives of the Recent National Institute of Neurological Disorders and Stroke Consensus Group Meeting. Stroke 2017; 48(9):2341-2.

Zivin JA, Grotta JC. Animal stroke models. They are relevant to human disease. Stroke. 1990;21(7):981-3.